These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

813 related items for PubMed ID: 22659193

  • 21. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Spriggs DR, Brady MF, Vaccarello L, Clarke-Pearson DL, Burger RA, Mannel R, Boggess JF, Lee RB, Hanly M.
    J Clin Oncol; 2007 Oct 01; 25(28):4466-71. PubMed ID: 17906207
    [Abstract] [Full Text] [Related]

  • 22. Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206.
    Onda T, Kobayashi H, Nakanishi T, Hatae M, Iwasaka T, Konishi I, Shibata T, Fukuda H, Kamura T, Yoshikawa H.
    Gynecol Oncol; 2009 Apr 01; 113(1):57-62. PubMed ID: 19181369
    [Abstract] [Full Text] [Related]

  • 23. Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancer.
    Janco JM, Hacker MR, Konstantinopoulos PA, Cannistra SA, Awtrey CS.
    J Minim Invasive Gynecol; 2011 Apr 01; 18(5):629-33. PubMed ID: 21803662
    [Abstract] [Full Text] [Related]

  • 24. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
    Fader AN, von Gruenigen V, Gibbons H, Abushahin F, Starks D, Markman M, Belinson J, Rose P.
    Gynecol Oncol; 2008 Apr 01; 109(1):33-8. PubMed ID: 18261784
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Shih KK, Chi DS, Barakat RR, Leitao MM.
    Gynecol Oncol; 2010 Mar 01; 116(3):364-9. PubMed ID: 19897231
    [Abstract] [Full Text] [Related]

  • 27. The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer.
    Kothari R, Nagel C, Koopmeiners JS, Ivy JJ, Geller M, Salani R, Argenta PA.
    Gynecol Oncol; 2010 Dec 01; 119(3):491-5. PubMed ID: 20888625
    [Abstract] [Full Text] [Related]

  • 28. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602.
    Onda T, Matsumoto K, Shibata T, Sato A, Fukuda H, Konishi I, Kamura T, Yoshikawa H, Japan Clinical Oncology Group.
    Jpn J Clin Oncol; 2008 Jan 01; 38(1):74-7. PubMed ID: 18258715
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Gould N, Sill MW, Mannel RS, Thaker PH, Disilvestro P, Waggoner S, Yamada SD, Armstrong DK, Wenzel L, Huang H, Fracasso PM, Walker JL.
    Gynecol Oncol; 2012 Apr 01; 125(1):54-8. PubMed ID: 22155262
    [Abstract] [Full Text] [Related]

  • 33. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
    Micha JP, Goldstein BH, Rettenmaier MA, Mattison J, Graham C, Birk CL, Brown JV.
    Gynecol Oncol; 2004 Sep 01; 94(3):719-24. PubMed ID: 15350364
    [Abstract] [Full Text] [Related]

  • 34. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
    Teneriello MG, Tseng PC, Crozier M, Encarnacion C, Hancock K, Messing MJ, Boehm KA, Williams A, Asmar L.
    J Clin Oncol; 2009 Mar 20; 27(9):1426-31. PubMed ID: 19224848
    [Abstract] [Full Text] [Related]

  • 35. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
    Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D, Southwest Oncology Group, Gynecologic Oncology Group.
    J Clin Oncol; 2003 Jul 01; 21(13):2460-5. PubMed ID: 12829663
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC.
    Gynecol Oncol; 2009 Dec 01; 115(3):377-81. PubMed ID: 19800107
    [Abstract] [Full Text] [Related]

  • 38. A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer.
    Fujiwara K, Aotani E, Hamano T, Nagao S, Yoshikawa H, Sugiyama T, Kigawa J, Aoki D, Katsumata N, Takeuchi M, Suzuki M.
    Jpn J Clin Oncol; 2011 Feb 01; 41(2):278-82. PubMed ID: 20937602
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.